Antibiotic mm 13902

Claim 2

A pharmaceutically acceptable di-basic salt of MM 13902 which is at least 50% pure wherein MM 13902 is a solid carboxylic acid of the molecular formula C 13 H 16 O 8 N 2 S 2 which in the form of a substantially pure sodium salt has the following characteristics: (a) in aqueous solution, it has a characteristic ultra violet spectrum with absorption maxima at about 305 nm and at about 225 nm substantially as shown in FIG. 1; (b) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infra-red spectrum which has absorption maxima at inter alia about 3450, 2950, 1750, 1620, 1510, 1400 and 1260 cm -1 ; (c) it has a characteristic N.M.R. spectrum when taken in D 2 O which spectrum possesses inter alia (i) a pair of low field doublets centered at approximately 2.85τ and 4.00τ with coupling constants of approximately 14 Hz; (ii) a doublet centered at approximately 8.55τ and (iii) a sharp singlet at approximately 8.00τ; (d) it possesses antibacterial activity against various species including inter alia, strains of Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhi and Pseudomonas aeruginosa; and (e) when mixed with ampicillin it synergizes its activity against organisms including strains of Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Proteus morganii and Staphylococcus aureus Russell.

Claim 3

A pharmaceutically acceptable di-basic salt of MM 13902 according to claim 1 in the form of an alkali metal salt.

Claim 4

A pharmaceutically acceptable di-basic salt of MM 13902 according to claim 1 in the form of the sodium, potassium, calcium, magnesium, aluminium or ammonium salt.

Claim 5

A pharmaceutically acceptable di-basic salt of MM 13902 according to claim 1 in the form of the di-sodium salt.

Claim 6

A pharmaceutically acceptable di-basic salt of MM 13902 according to claim 1 in the form of the di-potassium salt.

Claim 7

A pharmaceutically acceptable di-basic salt of MM 13902 according to claim 1 which is at least 70% pure.

Claim 8

A pharmaceutically acceptable di-basic salt of MM 13902 according to claim 1 which is at least 80% pure.

Claim 9

A pharmaceutically acceptable di-basic salt of MM 13902 according to claim 1 which is 90%-100% pure.

Claim 10

A process for the preparation of substantially pure MM 13902 in the form of a pharmaceutically acceptable di-basic salt wherein MM 13902 is a solid carboxylic acid of the molecular formula C 13 H 16 O 8 N 2 S 2 which in the form of a substantially pure sodium salt has the following characteristics: (a) in aqueous solution, it has a characteristic ultraviolet spectrum with absorption maxima at about 305 nm and at about 225 nm substantially as shown in FIG. 1; (b) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infra-red spectrum which has absorption maxima at inter alia about 3450, 2950, 1750, 1620, 1510, 1400 and 1260 cm -1 ; (c) it has a characteristic N.M.R. spectrum when taken in D 2 O, which spectrum possesses inter alia (i) a pair of low field doublets centered at approximately 2.85τ and 4.00τ with coupling constants of approximately 14 Hz; (ii) a doublet centered at approximately 8.55τ and (iii) a sharp singlet at approximately 8.00τ; (d) it possesses antibacterial activity against various species including inter alia, strains of Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhi and Pseudomonas aeruginosa; and (e) when mixed with ampicillin it synergizes its activity against organisms including strains of Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Proteus morganii and Staphylococcus aureus Russel; which comprises cultivating a MM 13902 producing strain of Streptomyces olivaceus having the same identifying characteristics as ATCC 31126 in a suitable medium containing an assimilable source of carbon, hydrogen and nitrogen until a significant amount of antibiotic activity has been imparted to said medium and recovering the substantially pure, pharmaceutically acceptable di-basic salt of MM 13902 from the culture medium.

Claim 11

A process for the preparation of substantially pure MM 13902 in the form of a pharmaceutically acceptable di-basic salt wherein MM 13902 is a solid carboxylic acid of the molecular formula C 13 H 16 O 8 N 2 S 2 which in the form of a substantially pure sodium salt has the following characteristics: (a) in aqueous solution, it has a characteristic ultraviolet spectrum with absorption maxima at about 305 nm and at about 225 nm substantially as shown in FIG. 1; (b) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infra-red spectrum which has absorption maxima at inter alia about 3450, 2950, 1750, 1620, 1510, 1400 and 1260 cm -1 ; (c) it has a characteristic N.M.R. spectrum when taken in D 2 O, which spectrum possesses inter alia (i) a pair of low field doublets centered at approximately 2.85τ and 4.00τ with coupling constants of approximately 14 Hz; (ii) a doublet centered at approximately 8.55τ and (iii) a sharp singlet at approximately 8.00τ; (d) it possesses antibacterial activity against various species including inter alia, strains of Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhi and Pseudomonas aeruginosa; and (e) when mixed with ampicillin it synergizes its activity against organisms including strains of Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Proteus morganii and Staphylococcus aureus Russel; which comprises cultivating a MM 13902 producing strain of Streptomyces olivaceus having the same identifying characteristics as ATCC 31126 in a suitable medium containing an assimilable source of carbon, hydrogen and nitrogen until a significant amount of antibiotic activity has been imparted to said medium and recovering the substantially pure, pharmaceutically acceptable di-basic salt of MM 13902 from the culture medium.

Claim 12

A process according to claim 9 for the preparation of substantially pure MM 13902 in the form of a pharmaceutically acceptable di-sodium or di-potassium salt wherein the substantially pure, pharmaceutically acceptable salt of MM 13902 is recovered as a di-sodium or di-potassium salt.